Skip to main content

Advertisement

SpringerLink
Log in

Periodontal Diseases/Treatment and Bisphosphonates

  • Systemic Diseases (N Buduneli, Section Editor)
  • Published:
Current Oral Health Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Host response against bacteria or their toxins eventually play a major role in alveolar bone destruction observed in periodontitis. Because of the role in bone resorption, bisphosphonates were applied as adjunct to non-surgical therapy. This review highlights the effects of bisphosphonates on clinical parameters as adjunct to periodontal treatment.

Recent Findings

Significant clinical and radiographic effects were observed in animal and human study models. In recent studies, local usage of the bisphosphonate gels was examined in periodontitis patients to prevent the systemic side effects. The mean pocket depth reduction, clinical attachment level gain, and the percentage of defect depth reduction were greater in bisphosphonate group.

Summary

Bisphosphonates appear to be effective in improving clinical outcomes of periodontal treatment. However, the clinical relevance still remains controversial because of the differences in methodology in the studies. New evidences from high-quality clinical trials are required to clear the clinical application of bisphosphonates as adjunct to non-surgical periodontal treatment in periodontitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999;4(1):1–6. The classification of the periodontal diseases. https://doi.org/10.1902/annals.1999.4.1.1.

    Article  CAS  PubMed  Google Scholar 

  2. Page RC, Offenbacher S, Schroeder HE, et al. Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol. 1997;14(1):216–48. https://doi.org/10.1111/j.1600-0757.1997.tb00199.x.

    Article  CAS  Google Scholar 

  3. Sun Y, Guo QM, Liu DL, Zhang MZ, Shu R. In vivo expression of Toll-like receptor 2, Toll-like receptor 4, CSF2 and LY64 in Chinese chronic periodontitis patients. Oral Dis. 2010;16(4):343–50. https://doi.org/10.1111/j.1601-0825.2009.01630.x.

    Article  CAS  PubMed  Google Scholar 

  4. de Paula EC, de Freitas PM, Esteves-Oliveira M, et al. Laser phototherapy in the treatment of periodontal disease. A review. Lasers Med Sci. 2010;25:781–92.

    Article  Google Scholar 

  5. Bender JS, Thang H, Glogauer M. Novel rinse assay for the quantification of oral neutrophils and the monitoring of chronic periodontal disease. J Periodontal Res. 2006;41(3):214–20. https://doi.org/10.1111/j.1600-0765.2005.00861.x.

    Article  CAS  PubMed  Google Scholar 

  6. Cobb CM. Non-surgical pocket therapy: mechanical. Ann Periodontol. 1996;1(1):443–90. https://doi.org/10.1902/annals.1996.1.1.443.

    Article  CAS  PubMed  Google Scholar 

  7. de Oliveira RR, Schwartz-Filho HO, Novaes AB Jr, Garlet GP, de Freitas Souza R, Taba M Jr, et al. Antimicrobial photodynamic therapy in the non-surgical treatment of aggressive periodontitis: cytokine profile in gingival crevicular fluid, preliminary results. J Periodontol. 2009;80(1):98–105. https://doi.org/10.1902/jop.2009.070465.

    Article  PubMed  Google Scholar 

  8. Haffajee AD. Systemic antibiotics: to use or not to use in the treatment of periodontal infections: that is the question. J Clin Periodontol. 2006;33(5):359–61. https://doi.org/10.1111/j.1600-051X.2006.00916.x.

    Article  PubMed  Google Scholar 

  9. Darveau RP, Tanner A, Page RC. The microbial challenge in periodontitis. Periodontol. 1997;14(1):12–32. https://doi.org/10.1111/j.1600-0757.1997.tb00190.x.

    Article  CAS  Google Scholar 

  10. Giannobile WV. Host-response therapeutics for periodontal diseases. J Periodontol. 2008;79(Suppl. 8):1592–600. https://doi.org/10.1902/jop.2008.080174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Peridontol. 2005;32(Suppl. 6):108–29. https://doi.org/10.1111/j.1600-051X.2005.00785.x.

    Article  CAS  Google Scholar 

  12. Tani-Ishii N, Minamida G, Saitoh D, Chieda K, Omuro H, Sugaya A, et al. Inhibitory effects of incadronate on the progression of rat experimental periodontitis by Porphyromonas gingivalis infection. J Periodontol. 2003;74(5):603–9. https://doi.org/10.1902/jop.2003.74.5.603.

    Article  CAS  PubMed  Google Scholar 

  13. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733–59. https://doi.org/10.1007/s00198-007-0540-8.

    Article  CAS  PubMed  Google Scholar 

  14. Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol. 2008;79(8):1569–76. https://doi.org/10.1902/jop.2008.080233.

    Article  CAS  PubMed  Google Scholar 

  15. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12):2961–78. https://doi.org/10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L.

    Article  CAS  PubMed  Google Scholar 

  16. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75–85. https://doi.org/10.1016/8756-3282(95)00445-9.

    Article  CAS  PubMed  Google Scholar 

  17. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol. 2000;18(6):1378–91. https://doi.org/10.1200/JCO.2000.18.6.1378.

  18. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150–7. https://doi.org/10.1200/JCO.2003.04.105.

    Article  CAS  PubMed  Google Scholar 

  19. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373–9. https://doi.org/10.1056/NEJMcp042806.

    Article  CAS  PubMed  Google Scholar 

  20. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21(22):4253–4. https://doi.org/10.1200/JCO.2003.99.132.

    Article  PubMed  Google Scholar 

  21. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–34. https://doi.org/10.1016/j.joms.2004.02.004.

    Article  PubMed  Google Scholar 

  22. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99–102.

    Article  CAS  PubMed  Google Scholar 

  23. Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc. 2005;71(2):111–3.

    PubMed  Google Scholar 

  24. Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol. 2005;128(6):738. https://doi.org/10.1111/j.1365-2141.2005.05382.x.

    Article  PubMed  Google Scholar 

  25. •• Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–1117. First cases in avascular necrosis of the jaws. https://doi.org/10.1016/S0278-2391(03)00720-1.

    Article  PubMed  Google Scholar 

  26. Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg. 2010;68(4):797–804. https://doi.org/10.1016/j.joms.2009.10.026.

    Article  PubMed  Google Scholar 

  27. Khosa AD, Nayyar MS, Beirne JC. Osteochemonecrosis of jaws and bisphosphonates. Ir Med J. 2007;100(3):410–1.

    CAS  PubMed  Google Scholar 

  28. Killeen AC, Rakes PA, Schmid MJ, Reinhardt RA, et al. Impact of local and systemic alendronate on simvastatin-induced new bone around periodontal defects. J Periodontol. 2012;83:1463–71.

    Article  CAS  PubMed  Google Scholar 

  29. Furlaneto FAC, Nunes NLT, Oliveira Filho IL, et al. Effects of locally administered tiludronic acid on experimental periodontitis in rats. J Periodontol. 2014;85:1291–301.

    Article  CAS  PubMed  Google Scholar 

  30. Carmen L, Mueller S, Tatiana MD, et al. Effect of alendronate on the progression of periodontitis induced by Porphyromonas gingivalis and Fusobacterium nucleatum: a study in rats. Clin Oral Investig. 2016;20:2565–73.

    Article  Google Scholar 

  31. Oktay AS, Chukkapalli SS, Rivera-Kweh MF, et al. Periodontitis in rats induces systemic oxidative stress that is controlled by bone-targeted. J Periodontol. 2015;86(1):137–45. https://doi.org/10.1902/jop.2014.140302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Almeida J, Ervolino E, Bonfietti LH, et al. Adjuvant therapy with sodium alendronate for the treatment of experimental periodontitis in rats. J Periodontol. 2015;86(10):1166–75. https://doi.org/10.1902/jop.2015.150166.

    Article  PubMed  Google Scholar 

  33. Buduneli E, Buduneli N, Vardar-Sengül S, Kardeşler L, Atilla G, Lappin D, et al. Systemic low-dose doxycycline and alendronate administration and serum interleukin-1 beta, osteocalcin, and C-reactive protein levels in rats. J Periodontol. 2005;76(11):1927–33. https://doi.org/10.1902/jop.2005.76.11.1927.

    Article  CAS  PubMed  Google Scholar 

  34. Buduneli E, Vardar-Sengül S, Buduneli N, Atilla G, Wahlgren J, Sorsa T. Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 gamma2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: effects of low-dose doxycycline and alendronate. J Periodontol. 2007;78(1):127–34. https://doi.org/10.1902/jop.2007.050451.

    Article  CAS  PubMed  Google Scholar 

  35. Bhavsar NV, Trivedi SR, Dulani K, Brahmbhatt N, Shah S, Chaudhri D. Clinical and radiographic evaluation of effect of risedronate 5 mg as an adjunct to treatment of chronic periodontitis in postmenopausal women. Osteoporos Int. 2016;27(8):2611–9. https://doi.org/10.1007/s00198-016-3577-8.

    Article  CAS  PubMed  Google Scholar 

  36. Grgić O, Kovačev-Zavišić B, Veljović T, Novaković-Paro J, Maravić T, Bajkin B. The influence of bone mineral density and bisphosphonate therapy on the determinants of oral health and changes on dental panoramic radiographs in postmenopausal women. Clin Oral Investig. 2017;21(1):151–7. https://doi.org/10.1007/s00784-016-1767-6.

    Article  PubMed  Google Scholar 

  37. Palomo L, Buencamino-Francisco MCA, Carey JJ, Sivanandy M, Thacker H. Is long-term bisphosphonate therapy associated with benefits to the periodontium in postmenopausal women? Menopause. 2011;18(2):164–70. https://doi.org/10.1097/gme.0b013e3181e8e2a2.

    PubMed  Google Scholar 

  38. Palomo L, Bissada NF, Liu J. Periodontal assessment of postmenopausal women receiving risedronate. Menopause. 2005;12(6):685–90. https://doi.org/10.1097/01.gme.0000184421.50696.34.

    Article  PubMed  Google Scholar 

  39. Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang HY, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol. 2005;76(7):1113–22. https://doi.org/10.1902/jop.2005.76.7.1113.

    Article  CAS  PubMed  Google Scholar 

  40. Rocha ML, Malacara JM, Sanchez-Marin FJ, et al. Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial. J Periodontol. 2004;75(12):1579–85. https://doi.org/10.1902/jop.2004.75.12.1579.

    Article  CAS  PubMed  Google Scholar 

  41. Mostafa B, Hamdy E, Nasif N. Combined effect of systemic bisphosphonates, calcium and vitamin D on alveolar bone in osteoporotic postmenopausal females having chronic periodontitis following surgical periodontal therapy. Life Sci J. 2012;9:613–22.

    Google Scholar 

  42. Tanna NK, Jeffcoat MK. Actonel® (risedronate) therapy for the maintenance of alveolar bone in adult chronic periodontitis. Health. 2013;5(07):12–7. https://doi.org/10.4236/health.2013.57A2002.

    Article  Google Scholar 

  43. Kochman RH, Kochman T, Stabholz A, et al. Bisphosphonate and estrogen replacement therapy in post-menopausal periodontitis. Isr Med Assoc J. 2004;6:173–7.

    PubMed  Google Scholar 

  44. Rackoff P. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Clin Interv Aging. 2009;4:207–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Sharma A, Raman A, Pradeep AR. Role of 1% alendronate gel as adjunct to mechanical therapy in the treatment of chronic periodontitis among smokers. J Appl Oral Sci. 2017;25(3):243–9. https://doi.org/10.1590/1678-7757-2016-0201.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Dutra BC, Oliveira AMSD, Oliveira PAD, et al. Effect of 1% sodium alendronate in the non-surgical treatment of periodontal intraosseous defects: a 6-month clinical trial. J Appl Oral Sci. 2017;25(3):310–7. https://doi.org/10.1590/1678-7757-2016-0252.

    Article  PubMed  PubMed Central  Google Scholar 

  47. • Pradeep AR, Kumari M, Rao NS, Naik SB. 1% alendronate gel as local drug delivery in the treatment of class II furcation defects: a randomized controlled clinical trial. J Periodontol. 2013;84(3):307–315. First study in the treatment of class II furcation defects with local bisphosphate gel. https://doi.org/10.1902/jop.2012.110729.

    Article  CAS  PubMed  Google Scholar 

  48. • Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel in adjunct to mechanotherapy in the treatment of aggressive periodontitis: a randomized controlled clinical trial. J Periodontol. 2012;83(1):19–26. First study in the treatment of aggressive periodontitis with local bisphosphate gel. https://doi.org/10.1902/jop.2011.110206.

    Article  CAS  PubMed  Google Scholar 

  49. • Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel as a local drug delivery system in the treatment of chronic periodontitis: a randomized, controlled clinical trial. J Periodontol. 2012;83(1):11–18. First study in the treatment of chronic periodontitis with local bisphosphate gel. https://doi.org/10.1902/jop.2011.110091.

    Article  CAS  PubMed  Google Scholar 

  50. Pradeep AR, Sharma A, Rao NS, Bajaj P, Naik SB, Kumari M. Local drug delivery of alendronate gel for the treatment of patients with chronic periodontitis with diabetes mellitus: a double-masked controlled clinical trial. J Periodontol. 2012;83(10):1322–8. https://doi.org/10.1902/jop.2012.110292.

    Article  CAS  PubMed  Google Scholar 

  51. Jeffcoat MK, Cizza G, Shih WJ, Genco R, Lombardi A. Efficacy bisphosphonates for the control of alveolar bone loss in periodontitis. J Int Acad Periodontol. 2007;9(3):70–6.

    PubMed  Google Scholar 

  52. Pradeep AR, Kanoriya D, Singhal S, et al. Comparative evaluation of subgingivally delivered 1% alendronate versus 1.2% atorvastatin gel in treatment of chronic periodontitis: a randomized placebo-controlled clinical trial. J Investig Clin Dent. 2017;8(3):e12215. https://doi.org/10.1111/jicd.12215.

  53. Veena HR, Prasad D. Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects. J Indian Soc Periodontol. 2010;14(1):40–5. https://doi.org/10.4103/0972-124X.65438.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Srisubut S, Teerakapong A, Vattraphodes T, et al. Effect of local delivery of alendronate on bone formation in bioactive glass grafting in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:11–6. https://doi.org/10.1016/j.tripleo.2007.04.022

    Article  Google Scholar 

  55. Välimäki VV, Moritz N, Yrjans JJ, Vuorio E, Aro HT. Effect of zoledronic acid on incorporation of a bioceramic bone graft substitute. Bone. 2006;38(3):432–43. https://doi.org/10.1016/j.bone.2005.09.016.

    Article  PubMed  Google Scholar 

  56. Rosenqvist K, Airaksinen S, Fraser SJ, Gordon KC, Juppo AM. Interaction of bioactive glass with clodronate. Int J Pharm. 2013;452(1-2):102–7. https://doi.org/10.1016/j.ijpharm.2013.04.059.

    Article  CAS  PubMed  Google Scholar 

  57. Rosenqvist K, Airaksinen S, Vehkamäki M, Juppo AM. Evaluating optimal combination of clodronate and bioactive glass for dental application. Int J Pharm. 2014;468(1-2):112–20. https://doi.org/10.1016/j.ijpharm.2014.04.017.

    Article  CAS  PubMed  Google Scholar 

  58. Abtahi J, Tengvall P, Aspenberg P. A bisphosphonate-coating improves the fixation of metal implants in human bone. A randomized trial of dental implants. Bone. 2012;50(5):1148–51. https://doi.org/10.1016/j.bone.2012.02.001.

    Article  CAS  PubMed  Google Scholar 

  59. Tengvall P, Skoglund B, Askendal A, Aspenberg P. Surface immobilized bisphosphonate improves stainless-steel screw fixation in rats. Biomaterials. 2004;25(11):2133–8. https://doi.org/10.1016/j.biomaterials.2003.08.049.

    Article  CAS  PubMed  Google Scholar 

  60. Wermelin K, Aspenberg P, Linderback P, et al. Bisphosphonate coating on titanium screws increases mechanical fixation in rat tibia after two weeks. J Biomed Mater Res A. 2008;86(1):220–7. https://doi.org/10.1002/jbm.a.31583.

    Article  PubMed  Google Scholar 

  61. Wermelin K, Suska F, Tengvall P, Thomsen P, Aspenberg P. Stainless steel screws coated with bisphosphonates gave stronger fixation and more surrounding bone. Histomorphometry in rats. Bone. 2008;42(2):365–71. https://doi.org/10.1016/j.bone.2007.10.013.

    Article  CAS  PubMed  Google Scholar 

  62. Abtahi J, Henefalk G, Aspenberg P. Randomised trial of bisphosphonate-coated dental implants: radiographic follow-up after five years of loading. Int J Oral Maxillofac Surg. 2016;45(12):1564–9. https://doi.org/10.1016/j.ijom.2016.09.001.

    Article  CAS  PubMed  Google Scholar 

  63. Zuffetti F, Testori T, Capelli M, Rossi MC, del Fabbro M. The topical administration of bisphosphonates in implant surgery: a randomized split-mouth prospective study with a follow-up up to 5 years. Clin Implant Dent Relat Res. 2015;17:e168–76. https://doi.org/10.1111/cid.12151.

    Article  PubMed  Google Scholar 

  64. Hiltunen AK, Skogman ME, Rosenqvist K et al. Bioactive glass combined with bisphosphonates provides protection against biofilms formed by the periodontal pathogen Aggregatibacter actinomycetemcomitans Int J Pharm. 2016;501:211–20. https://doi.org/10.1016/j.ijpharm.2016.02.006

  65. Reshamwala SM, Mamidipally C, Pissurlenkar RR, et al. Evaluation of use of risedronate as an antibiofilm agent. J Med Microbiol. 2016;65(1):9–18. https://doi.org/10.1099/jmm.0.000193.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Dentistry, Department of Periodontology, Ege University, Izmir, Turkey

    Pınar Meriç & Önder Gürlek

Authors
  1. Pınar Meriç
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Önder Gürlek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pınar Meriç.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Systemic Diseases

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meriç, P., Gürlek, Ö. Periodontal Diseases/Treatment and Bisphosphonates. Curr Oral Health Rep 5, 1–6 (2018). https://doi.org/10.1007/s40496-018-0163-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40496-018-0163-5

Keywords

Search

Navigation